Randomized phase III trial of surgery plus neoadjuvant TS-1 and cisplatin compared with surgery alone for type 4 and large type 3 gastric cancer: Japan Clinical Oncology Group Study (JCOG 0501)
Latest Information Update: 12 Apr 2023
Price :
$35 *
At a glance
- Drugs Cisplatin (Primary) ; Gimeracil/oteracil/tegafur (Primary)
- Indications Adenocarcinoma; Gastric cancer
- Focus Therapeutic Use
- 25 Jan 2020 Results of Surrogate indicators of survival in patients who received neoadjuvant chemotherapy for type 4 and large type 3 gastric cancer in JCOG0501 has been presented at the 2020 Gastrointestinal Cancers Symposium
- 20 Sep 2016 Status changed from active, no longer recruiting to completed.
- 19 Jul 2013 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan record.